Provided by Tiger Trade Technology Pte. Ltd.

Mesoblast

17.29
+0.79004.79%
Post-market: 17.290.00000.00%19:30 EDT
Volume:296.63K
Turnover:5.11M
Market Cap:2.24B
PE:-38.94
High:17.40
Open:16.98
Low:16.98
Close:16.50
52wk High:21.50
52wk Low:12.66
Shares:129.69M
Float Shares:84.12M
Volume Ratio:1.21
T/O Rate:0.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4440
EPS(LYR):-0.8457
ROE:-9.86%
ROA:-4.11%
PB:3.94
PE(LYR):-20.44

Loading ...

Post-Approval Safety Risks Threaten Mesoblast’s Ryoncil Commercialization in Fragile Pediatric SR-aGVHD Market

TIPRANKS
·
Aug 31

Mesoblast Earnings Call: RYONCIL Fuels Growth Story

TIPRANKS
·
Aug 30

Mesoblast Price Target Raised to $39.00/Share from $35.00 by Piper Sandler

Dow Jones
·
Aug 28

Mesoblast FY EPS $(0.04) Misses $0.01 Estimate, Sales $120.250M Beat $66.000M Estimate

Benzinga Earnings
·
Aug 27

Reported Earlier, Mesoblast Reports FY2026 Total Revenue Of $120.3M Up From $17.2M, Net Loss Narrows 44% To $57.5M From $102.1M

Benzinga Earnings
·
Aug 27

Mesoblast Fiscal 2026 Loss Narrows; Revenue Up

MT Newswires Live
·
Aug 27

Mesoblast Reports Substantial Revenue Growth to US$120M

GlobeNewswire
·
Aug 27

Mesoblast Flags Risks Around 2026 Outlook and Stem Cell Strategy

TIPRANKS
·
Aug 27

Mesoblast Files 2026 Form 20-F, Affirms Status as Well-Known Issuer

TIPRANKS
·
Aug 27

Mesoblast Limited - There Can be no Assurance That We Will Ever Achieve or Maintain Profitability

THOMSON REUTERS
·
Aug 27

Mesoblast Limited - Anticipate That We May Continue to Incur Significant Losses for Foreseeable Future

THOMSON REUTERS
·
Aug 27

Mesoblast Limited Expected to Post a Loss of 3 Cents a Share - Earnings Preview

Reuters
·
Aug 25

Mesoblast Financial Results and Corporate Update Webcast

GlobeNewswire
·
Aug 24

Mesoblast Increases Director Philip Krause’s Equity-Based Incentives

TIPRANKS
·
Aug 24

Mesoblast Stock Leads 3 Fast Growing ASX Picks With Strong Insider Ownership

Simply Wall St.
·
Aug 23

Mesoblast Stock Leads 3 Australian Growth Shares With Strong Earnings Expectations

Simply Wall St.
·
Aug 23

Mesoblast Stock Leads 3 High Growth Insider Owned ASX Shares To Watch

Simply Wall St.
·
Aug 21

Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial

TIPRANKS
·
Aug 17

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

GlobeNewswire
·
Aug 17

Mesoblast Reaches Pivotal Phase 3 Milestone in Chronic Back Pain Trial

TIPRANKS
·
Aug 17